GlassScriptPhysician profile
Thomas A Brown
NPI 1700906948
$10,519.06
in general payments reported to CMS, 2019-2025
37 companies · $2,685 in 2025
The $2,685 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $692 · 2021: $1,029 · 2022: $1,249 · 2023: $1,694 · 2024: $2,344 · 2025: $2,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,599 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,599.05 |
| Education | $124.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,105.48 | 2019-2025 | Rinvoq, Creon, Viberzi |
| Pfizer INC. | $897.34 | 2019-2025 | |
| Janssen Biotech, INC. | $596.75 | 2023-2025 | Tremfya, Stelara, Simponi |
| Boston Scientific Corporation | $570.20 | 2019-2025 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $565.93 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $521.24 | 2019-2025 | Epclusa |
| Celgene Corporation | $460.89 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $458.10 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $337.14 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $316.41 | 2024-2025 | Zenpep, Vowst |
| Qol Medical, LLC | $306.76 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $301.03 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $299.03 | 2023-2025 | Omvoh |
| Genzyme Corporation | $283.77 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.25 | 2022-2025 | Xifaxan |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $206.45 | 2024-2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $160.31 | 2024-2025 | Iqirvo |
| Medtronic, INC. | $154.15 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $152.83 | 2019-2021 | |
| Braintree Laboratories, INC. | $106.26 | 2024-2025 | Suflave, Sutab |
| E.R. Squibb & Sons, L.L.C. | $75.20 | 2022 | |
| Novo Nordisk INC | $67.01 | 2025 | Wegovy |
| Ardelyx, INC. | $54.21 | 2024-2025 | Ibsrela |
| Vivus LLC | $38.67 | 2021 | |
| Ironwood Pharmaceuticals, INC | $33.97 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $33.74 | 2023-2025 | Rebyota |
| Enterra Medical, INC. | $30.25 | 2022-2023 | |
| Organon LLC | $28.92 | 2023 | Hadlima |
| Dova Pharmaceuticals | $26.12 | 2019 | |
| Redhill Biopharma INC. | $20.52 | 2022 | |
| Glaxosmithkline, LLC. | $18.25 | 2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $17.88 | 2019 | |
| Allergan, INC. | $13.05 | 2020 | |
| Mallinckrodt Hospital Products INC. | $12.79 | 2023 | Terlivaz |
| Shionogi INC | $11.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 | |
| Erbe USA INC | $5.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.